#1
Taiwan-madeCOVID-19 vaccine
Innovation for your better lives.
COVID-19 vaccine
#1
MRCT Phase III study
evaluated EV vaccine
5
Clinical-stage
R&D projects
>60%
R&D
workforce
GMPcertificated
PIC/S GMP vaccine manufacturing facility我們的故事OUR STORY
MVC is a biopharmaceutical company focusing on the development and mass production of vaccines and biologics. We have PIC/S GMP certified cell culture commercial mass production capabilities, and target global and regional infectious diseases to develop novel vaccines and affordable biosimilar drugs via international alliances.
We are based in Taiwan and human health is our priority. Since MVC was established, we are dedicated to developing countermeasures for the prevention and treatment of emerging infectious diseases such as COVID-19, Enterovirus A71, Dengue, and Influenza vaccines. Our achievements to date prove that our products and technologies deliver.
We believe the right to health is a fundamental part of our human rights and also the foundation of global development. Vaccines and biologics are key strategies to approach the goal. We are continuing to provide safe, effective, and qualified medical products and aim to become the R&D and mass production hub in the Asia-Pacific region. We are introducing our products to the world to protect people from the threat of numerous diseases.
MILESTONESMILESTONES
As we reflect on our past,
we will continue to strive for a better future.
2021
- MVC announced efficacy and safety results for EV71 vaccine Phase 3 MRCT clinical trial and submitted the NDA application to TFDA.
- MVC COVID-19 Vaccine obtained Taiwan EUA approval.
2020
- MVC signed a license agreement with US NIH for COVID-19 vaccine.
- MVC SARS-CoV-2 qPCR Kit earned CE marking and Taiwan MOHW's approval of Specific Medical Device Manufacturing.
- MVC initiated Phase I and Phase II trials for COVID-19 vaccine.
2019
- MVC's EV71 vaccine obtained TFDA's PIC/S GMP certification.
- MVC completed the enrollment of Phase III MRCT for EV71 Vaccine in Taiwan and Vietnam.
2018
- MVC listed on Taiwan OTC/TaiSDAQ market (TPEx:6547)
- MVC signed an exclusive distribution agreement for GC Pharma's quadrivalent influenza vaccine and receives TFDA's approval to start Phase III clinical trial.
2017
- MVC provided the CSR of EV71 vaccine Phase II study to TFDA.
- EV71 vaccine Phase III study was approved by TFDA.
- MVC signed a licensing agreement with Taiwan CDC for BCG vaccine and snake antivenoms.
- The H7N9 Phase I/II study passed the GCP inspection.
2016
- MVC's EV71 vaccine won Taiwan's National Innovation Award for being the first EV71 vaccine for 2~6 months old babies.
- MVC licensed in US NIH's live attenuated dengue vaccine (TV003/TV005) and obtained the rights to develop, produce, sell and sublicense in 17 countries.
- MVC inaugurated Taiwan's first cell-based vaccine manufacturing plant.
- MVC signed an agreement with US CDC to co-develop dengue VLP vaccine.
- MVC signed an agreement with WHO/UCAB, mAbXience, Libbs and SPIMACO to form a consortium to co-develop biosimilar palivizumab against RSV.
2015
- MVC was granted National Innovation Award for the application of cell-based production technologies in mock-up vaccine manufacturing.
- MVC listed on Taiwan OTC stock market (emerging stock market, stock code: 6547)
- MVC entered the Phase I/II study for H7N9 vaccine.
2014
- MVC entered the Phase II study for EV71 vaccine.
- MVC signed a licensing agreement with NHRI for H7N9 vaccine.
- Groundbreaking ceremony of MVC vaccine plant was held at Hsinchu Biomedical Science Park.
2013
- MVC office established in Neihu District, Taipei and fund raising for NT $1.2 billion initiated for vaccine plant and R&D center at Zhubei City.
- MVC signed the technology-transfer agreements with NHRI for EV71 vaccine technology and its Phase I clinical results.
2012
- MVC conducted the Phase I study for H5N1 vaccine.
- Medigen Vaccinology Corp. (MVC) was founded.
2009
- "A-Team" cooperated with NHRI for cell-based H1N1 and H5N1 influenza vaccine development.